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Abstract
Human leukocyte antigen (HLA) is a group of
proteins coded by the major histocompatibility
complex (MHC) and is a vital part of the human
immune response. HLA allows abnormal cells
to be destroyed by cytotoxic T-cells by
presenting antigens to the cell surface. In
tumors, however, there is diminished HLA
expression, allowing cells to bypass the
immune system. Experiments were conducted
to determine the effects of various drug
epigenetic modifiers on HLA expression in
MDA-MB-231 cells, a human breast cancer cell
line. HLA expression was compared between
control and drug treatments using flow
cytometry. Initial results found that HLA-ABC
expression is increased in cells treated
individually with the drugs 5-Azacytidine and
Vorinostat. We are continuing to test
combinations of these drugs, along with the
addition of gamma-Interferon, an immune
cytokine known to upregulate HLA-ABC
expression. Furthermore, we would like to
study how two other HLA proteins, HLA-E and
HLA-G, can be affected by these epigenetic
modifiers. Effective increases in HLA
expression can be beneficial to cancer
immunotherapy.

MDA-MB-231 Cell Culture
Cells grown in 25 cm2 with
Iscove's Modified Dulbecco's Medium

Treatment Selection
Control and experimental flasks made

Figure 1. Flow cytometry
fluorescence of HLA-ABC
in MDA-MB-231 treated
with 5-Azacytidine. A
strong increase in HLA
expression is shown as a
result of the drug treatment.

Figure 2. Flow cytometry
fluorescence of HLA-ABC
in MDA-MB-231 treated
with Vorinostat. A
noticeable increase in HLA
expression is shown as a
result of the drug treatment.

Treatment Marking
Anti-HLA Class I antibodies added to
each treatment for visualization of HLA

Figure 3. Flow cytometry fluorescence of HLA-ABC in
MDA-MB-231 under different conditions. Control (no
drug) is represented by purple, IFNγ is represented by light
green, and IFNγ with 5-Azacytidine is represented by pink.
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• We would like to investigate into other
components of MHC Class I, such as
HLA-G and HLA-E.
• Moreover, we are interested in
investigating HLA expression of MHC
Class II, as it has been speculated that the
upregulation of MHC Class II in tumor
cell lines may improve chances of
recognition by the immune system [4]
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Table 1. Flow Cytometry Fluorescence of
HLA-ABC, shown as mean log values.
A variety of treatments were done across 5
separate experiments. Treatments that were not
applied are noted as a dash (–). Every trial
shows a clear increase in HLA expression from
each experimental treatment. For each drug
treatment, percent increase relative to the
control is shown.

• 5-Azacytidine and Vorinostat both
individually upregulate HLA-expression
in MDA-MB-231.
• Gamma Interferon also demonstrated a
strong upregulation in HLA-ABC
expression (Table 1).
• Although a combination of Gamma
Interferon and Vorinostat was found to
augment expression, a combination of
Gamma Interferon with 5-Azacytidine
lowered expression below those of
individual drug treatments alone, while
still above that of control conditions
(Figures 3 and 4).

Future Experiments

Flow Cytometry
HLA-ABC analyzed via flow cytometry

Introduction
• Previous experimentation in cancer
immunotherapy have demonstrated that
tumor cells are able to proliferate via
downregulation of MHC class I, thus
bypassing a T cell-mediated immune
response [1].
• Vorinostat and interferons have been
shown to restore HLA expression in
Merkel cell carcinoma [2].
• DNA methyltransferase (DNMT)
inhibitors like 5-Azacytidine have been
found to lack curative effects but still
enhance the activity of cytotoxic drugs
for treating acute myeloid leukemia and
lung cancer [3]
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Figure 4. Flow cytometry fluorescence of HLA-ABC in
MDA-MB-231 under different conditions. Control (no
drug) is represented by purple, Vorinostat is represented by
light green, IFNγ is represented by pink, and IFNγ with
Vorinostat is represented by blue.
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